Breaking

MHRA approves new biosimilar●AstraZeneca Q1 results exceed forecast●NICE updates TA guidance for oncology●Roche launches Phase III rare disease trial●FDA grants breakthrough therapy designation●UK Biobank releases genomic dataset●GSK acquires clinical-stage biotech firm●EMA recommends novel gene therapy●MHRA approves new biosimilar●AstraZeneca Q1 results exceed forecast●NICE updates TA guidance for oncology●Roche launches Phase III rare disease trial●FDA grants breakthrough therapy designation●UK Biobank releases genomic dataset●GSK acquires clinical-stage biotech firm●EMA recommends novel gene therapy●

UK Clinical Trial Reforms 2026: Accelerating Approvals

The UK clinical trial regulation package, taking effect on 28 April 2026, is designed to deliver faster, more predictable approvals while preserving participant protections. Its headline operational c

Editorial|10 June 2026

Cancer

Latest Research & Insights

Expert analysis from pharmaceutical industry leaders

View All Articles→

Research

Amyloid therapies reach limits as multi-target strategies advance

The approval of amyloid-targeting monoclonal antibodies by the MHRA marked a clear regulatory and scientific milestone in Alzheimer’s disease treatment. These agents demonstrated that disease-modifyin

Editorial·10 June 2026